in 25 days Kaiser Permanente — Kaiser Northwest's Zepbound criteria move to the rev 10/08/2026 document — cite that version in an appeal from this date See the changelog
WalletNoise

Express Scripts (Evernorth / Cigna)

PBM standard commercial template (National Preferred Formulary) · updated October 16, 2026

Coverage right now

Kept both Wegovy and Zepbound single-dose pens preferred through the 2025 upheaval. 2026 NPF: Zepbound pens, Wegovy (pens, HD, tablets), and Foundayo all preferred — but Zepbound KwikPens and vials are excluded (device-level steering), and Saxenda is excluded in favour of generic liraglutide. PA criteria run through the Cigna National Formulary policies, which since June 2026 are published one per drug rather than as a single combined document. The 2027 NPF exclusions list, published 08/01/2026, carries this class forward with no change: the same two Zepbound presentations excluded, the same six agents named as preferred alternatives, and Saxenda still excluded in favour of generic liraglutide — so the device-level steering survives into the 2027 plan year.

Drug status

DrugStatusDetailConfidence
Zepbound® (tirzepatide)Preferred
from Jan 1, 2026
Single-dose pens preferred on the 2026 National Preferred Formulary. KwikPens and vials EXCLUDED (alternatives: Zepbound pens, Wegovy, Foundayo, liraglutide). express-scripts.com· express-scripts.comhigh
Wegovy® (semaglutide injection)Preferred
from Jan 1, 2026
Pens and HD preferred. express-scripts.com· express-scripts.comhigh
Wegovy® tablets (oral semaglutide)Preferred
from Jan 5, 2026
Wegovy tablets preferred on the 2026 NPF. express-scripts.com· express-scripts.comhigh
Foundayo™ (orforglipron)Preferred
from Jul 1, 2026
Listed preferred in the 07/01/2026 NPF — one of the fastest adds of the new oral. express-scripts.com· express-scripts.comhigh
Saxenda® (liraglutide)Excluded
from Jan 1, 2026
Excluded from the 2026 National Preferred Formulary. Listed under 'Excluded Medications/Products at a Glance' with the brand-exclusion-with-generic-equivalent marker, meaning generic liraglutide is the covered agent. Not on the covered PDL. A benefit exclusion is appealed differently from a PA denial. express-scripts.com· express-scripts.comhigh

What these rules come to in dollars — every dose, priced under this coverage:

What preferred, covered and exception only mean
Preferred
On the formulary at the plan's best tier for this class. Usually still needs prior authorization — preferred is not the same as automatic.
Covered
On the formulary, but not the plan's first choice for this class. Often a higher copay tier than a preferred drug.
Non preferred
On the formulary at a disadvantaged tier, or reachable only after trying a preferred drug first.
Exception only
Not routinely covered. Obtainable only through a formulary-exception request that meets the plan's published criteria.
Excluded
Not on the formulary at all. A benefit exclusion is a different fight from a PA denial and is appealed differently.
Varies
The payer's own documents differ by plan or line of business, so a single answer here would be wrong.
Unknown
Not yet verified against a primary document. Recorded as absent rather than guessed.
N/A
Not applicable to this payer.

Prior authorization criteria

high
PA required
Yes, where the plan covers weight loss (EncircleRx adds employer-level eligibility management; participating plans cap member GLP-1 cost at <= $200/month).
Initial BMI
WEIGHT LOSS: baseline BMI >= 30, OR baseline BMI >= 27 with >= 1 weight-related comorbidity. Baseline means before any GLP-1 or GLP-1/GIP agonist, so weight already lost on one does not disqualify you. Pediatric (12 to under 18): BMI >= 95th percentile for age and sex, and only on Wegovy INJECTION or liraglutide — Wegovy tablets, Zepbound and Foundayo are adults-only at >= 18. Weight loss is not the only approvable indication, and the others set their own bar: OBSTRUCTIVE SLEEP APNEA (Zepbound only) at baseline BMI >= 30 with a sleep study diagnosing moderate-to-severe OSA and an apnea-hypopnea index or respiratory event index >= 15 events per hour, and neither central sleep apnea nor Cheyne-Stokes respiration. CARDIOVASCULAR RISK REDUCTION (Wegovy injection and Wegovy tablets) at baseline BMI >= 27 with established CV disease evidenced by a prior myocardial infarction, a prior stroke (a TIA does not count) or symptomatic peripheral arterial disease (claudication with ankle-brachial index < 0.85, a revascularization procedure, or amputation for atherosclerotic disease). MASH/NASH (Wegovy injection only) carries NO BMI threshold at all: it needs stage F2 or F3 fibrosis and no cirrhosis, documented by biopsy within 3 years or VCTE, MRE or an ELF score of 9.2 to 10.5 within 6 months, plus a managed metabolic risk factor and alcohol under 20 g/day (female) or 30 g/day (male).
Comorbidities
Hypertension, T2D, dyslipidemia, OSA, cardiovascular disease, knee osteoarthritis, asthma, COPD, MASLD/NAFLD, PCOS, or coronary artery disease — the broadest published list among major PBMs. This list lowers the weight-loss BMI bar to 27 and is used by that indication only; the other indications name their own qualifying conditions instead.
Lifestyle requirement
Trial of behavioral modification and dietary restriction for at least 3 months, AND concomitant use with behavior modification and reduced-calorie diet. The 3-month PRIOR trial is a weight-loss criterion only — the OSA, cardiovascular-risk and MASH indications ask for concomitant behavioral modification and a reduced-calorie diet and nothing retrospective, so a member with no documented 3-month history is not shut out of those routes. MASH additionally requires the prescription to come from or be made in consultation with an endocrinologist, gastroenterologist or hepatologist, and cardiovascular-risk approval requires optimized CV pharmacotherapy alongside it.
Initial authorization
Weight loss: 8 (Wegovy, Zepbound, Foundayo) · 4 (liraglutide/Saxenda). The OSA, cardiovascular-risk and MASH indications approve for 1 YEAR instead, so which indication the request is written under decides how soon the member faces a renewal.
Reauthorization
Weight loss: lost >= 5% of baseline body weight (>= 4% liraglutide; pediatric: BMI reduction >= 1%), measured from the same baseline the initial criteria use. Reauthorization lasts 1 year. The other indications renew on their own terms: continuing Zepbound for OSA after a year needs >= 10% of baseline body weight lost AND prescriber-reported stability in OSA signs or symptoms — a higher weight bar than the weight-loss route it is often confused with; continuing Wegovy for MASH needs no worsening of fibrosis or MASH, still no cirrhosis, and the specialist involvement the initial approval required; cardiovascular-risk approval has no separate continuation block, so the same criteria are met again each year.
Step therapy
None in the PA policy; steering happens at device level via formulary exclusions (KwikPen/vial excluded).
Quantity limits
Zepbound: 2 mL (4 pens or vials) per 28 days retail; 6 mL (12) per 84 days home delivery — no overrides (policy cnf_840). Separately, and across the whole class: only ONE claim for ONE GLP-1 or GLP-1/GIP agonist is approved every 21 days, on fills of a 28-day supply or more, with no overrides recommended for any of Saxenda, Foundayo, Wegovy, Wegovy HD, Wegovy tablets or Zepbound (policy cnf_894, reviewed 01/07/2026, revised 02/04/2026 and 04/08/2026). The 21-day limit APPLIES only to retail fills, but it counts retail and mail history together — so a mail-order fill still uses up the window a later retail fill needs. Switching product mid-month is what it stops.

Primary criteria document: static.cigna.com· static.cigna.com· static.cigna.com· static.cigna.com· static.cigna.com· static.cigna.com

Exceptions and appeals

Appeal deadline
180 days
Deadline detail
180 days from receipt of the adverse determination (Level 2: 90 days).
Exception route
ESI runs TWO tracks and the choice is not the member's: a CLINICAL coverage review is a request judged on medical criteria, an ADMINISTRATIVE one is a request judged on the plan's benefit design — which is what a formulary exclusion is. Clinical: prescriber ePA via esrx.com/PA, ExpressPAth, CoverMyMeds or Surescripts, or the Coverage Review Department on 800-753-2851, or a coverage review form to fax 877-329-3760. Administrative: the member or their representative must submit the request IN WRITING to Express Scripts, Attn: Benefit Coverage Review Department, P.O. Box 66587, St. Louis, MO 63166-6587 — there is no ePA path and no prescriber shortcut for this one. Zepbound KwikPens, Zepbound vials and Saxenda are excluded by benefit design, so they are the administrative track, and they are exactly the GLP-1 denials this payer generates most.
Turnaround
ESI states nearly all coverage reviews complete within two days of complete information; ePA can return in minutes. Published decision limits: urgent 72 hours, standard pre-service 15 days at retail but 5 days through home delivery, post-service 30 days. The same limits apply again to a level 1 appeal, except that pre-service is 15 days whichever channel you used.
Where
Clinical appeals (a PA denial on medical criteria): Express Scripts, Attn: Clinical Appeals Department, P.O. Box 66588, St. Louis, MO 63166-6588 · fax 877-852-4070. Administrative appeals (a benefit-design denial, which is what a formulary exclusion is): Express Scripts, Attn: Administrative Appeals Department, P.O. Box 66587, St. Louis, MO 63166-6587 · fax 877-328-9660. The two boxes differ by one digit and the fax numbers are unrelated, so an exclusion appeal sent to the clinical department is the easy mistake here.

Source: slu.edu· express-scripts.com

Dated changes

  • Jan 1, 2026 2026 NPF year began — 48 new exclusions, GLP-1 anti-obesity class core retained source
  • Jan 1, 2026 Saxenda excluded from the National Preferred Formulary for the 2026 plan year; generic liraglutide is the covered agent source
  • Jul 1, 2026 NPF document lists Foundayo preferred; Zepbound KwikPens and vials excluded source
  • Oct 1, 2026 Both NPF documents re-issued with 10/01/2026 revision stamps; the Weight Loss row is unchanged — Zepbound KwikPens and vials stay excluded, with liraglutide, Foundayo, Wegovy HD, Wegovy pens, Wegovy tablets and Zepbound pens as the preferred alternatives. Quote the 10/01/2026 stamp in an appeal, not the 07/01/2026 one source
  • Jun 17, 2026 Cigna replaced the single weight-loss GLP-1 prior authorization policy with one policy per drug — the criteria did not change, but if you are citing the old combined document in an appeal it now returns a dead link, so quote the policy for your own drug instead source
  • Jan 1, 2027 The 2027 National Preferred Formulary keeps the weight-loss class exactly as 2026 left it: Zepbound KwikPens and vials excluded, with liraglutide, Foundayo, Wegovy HD, Wegovy pens, Wegovy tablets and Zepbound pens as the preferred alternatives, and Saxenda excluded in favour of generic liraglutide. Nothing you have to do changes on this date — but cite the 2027 exclusions list, not the 2026 one, in an appeal about a 2027 fill source
Criteria cited are Cigna National Formulary coverage policies used with ESI-administered Cigna business; the ESI NPF standard tracks these closely but self-funded clients customize. Widely-indexed secondary sources claim Wegovy injection, Wegovy tablets and Zepbound pens are excluded from the 2026 NPF and that Zepbound vials are the preferred agent — that is backwards, and both of ESI's own PDFs say so. NPE1702 (the covered PDL, effective Jan 1 - Dec 31 2026) lists FOUNDAYO, liraglutide, WEGOVY HD, WEGOVY PENS, WEGOVY TABLETS and ZEPBOUND PEN as covered; the exclusions document lists ZEPBOUND KWIKPENS and ZEPBOUND VIALS as the excluded items, with those same six as their preferred alternatives. Both were re-issued effective 10/01/2026 and now carry the PRMT22157-26 (10/01/2026) and EXCL-NPF-26 (10/01/2026) revision stamps; the Weight Loss row is identical across that revision, and NPE1702 still states it is effective January 1 through December 31, 2026. Trust the primary document — a web search run on 2026-09-10, and again on 2026-10-03, still returned the backwards version. The combined PA policy this file cited for months, cnf_684, was not merely withdrawn: Cigna SPLIT it into one policy per drug, all reviewed 06/17/2026, which is why the old URL 404s from static, chk.static and v.static alike while its directory neighbours answer. The five successors are cited above and carry the same BMI, comorbidity, lifestyle, duration and reauthorization criteria the combined policy did, read in full on 2026-09-10. The split is also what makes the pediatric line above drug-specific rather than class-wide: only the liraglutide and Wegovy INJECTION policies contain a 12-to-under-18 pathway, and the Wegovy TABLET policy does not, which the single combined document did not let anyone see. Do not cite the EncircleRx benefit-exclusion-override policies as the PA criteria: they now run cnf_1011 through cnf_1020, two per drug, and their own filenames carry their bar — bmi_32 or bmi_35 — so citing one would silently replace the >= 30 / >= 27-with-comorbidity criteria above with a stricter one. That trap has been walked into twice before under the old numbering (ip_0621 at BMI >= 32, cnf_950 at BMI >= 35). cnf_360 is a third shape of the same trap: it is live and its name looks right, but it is the DIABETES GLP-1 policy covering Mounjaro, Ozempic, Rybelsus, Trulicity and Victoza, not a weight-loss policy at all. A fourth shape of the trap comes from the split itself: the five policies do not carry the same INDICATIONS as each other, so citing the wrong drug's policy for a route it does not contain is an easy denial. Read in full on 2026-10-12, the map is: cnf_1006 Zepbound — weight loss and OSA; cnf_1007 Foundayo — weight loss only, adults only; cnf_1008 liraglutide — weight loss, adult and pediatric; cnf_1009 Wegovy tablets — weight loss and cardiovascular risk reduction, with no pediatric and no MASH route; cnf_1010 Wegovy injection — all four, weight loss adult and pediatric, cardiovascular risk reduction and MASH. So there is no OSA route to any drug but Zepbound and no MASH route to anything but the Wegovy injection, and the tablet is not a substitute for the injection on either. This mirrors the drugs' own labels, which were read the same day and grant the tablet cardiovascular risk reduction and weight reduction in adults while reserving MASH and the 12-and-over pathway to the injection. The appeal block previously rested on an hr.jhu.edu mirror that refused every client for ten days; it now cites a live employer mirror of the same ESI process description, which carries the 180-day, Level-2 90-day, St. Louis address, fax and urgent-phone claims verbatim. It stays MEDIUM because an employer's mirror of ESI's process is not ESI's own publication. Cite the SECTION for the door you are actually coming through, not just the policy: cnf_1006 section 2 for Zepbound in obstructive sleep apnea, cnf_1010 sections 3 and 4 for Wegovy injection in cardiovascular risk reduction and in MASH/NASH, and cnf_1009 section 2 for Wegovy tablets in cardiovascular risk reduction — in each of the five policies only the FIRST numbered indication is weight loss, so quoting the policy without the section invites a denial on the wrong criteria.
These are each payer's standard template. Employer plans customize them, so the same PBM can cover a drug for one employer and exclude it for another — a status here is a starting point, not your plan. A benefit exclusion is also a different fight from a PA denial. Always request your own plan's criteria in writing; you are entitled to them.